ReviewFrontiers in cell and developmental biology2026
Ubiquitination mediated by RING-type E3 ligases in the progression of digestive system tumors: mechanistic insights and potential therapeutic strategies.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination is a core mechanism for the precise regulation of protein fate, closely related to the occurrence and development of many diseases. As the most critical enzymes in the ubiquitination process, really interesting new gene (RING)-type E3 ubiquitin ligases play an important role in regulating the malignant behaviors of tumor cells. As tumor promoters or suppressors, different types of RING-type E3 ligases have shown various prognostic values in cancer patients. This review provides a comprehensive overview of the effects of RING-type E3 ligases on the progression of digestive system tumors, highlighting the key signaling pathways involved in regulating tumor proliferation, invasion, migration, and metastasis. Additionally, it discusses the relationship between the expression of RING-type E3 ligases and poor patient prognosis, providing a foundation for clinical screening of valuable prognostic markers. Furthermore, this review summarizes recent research progress, mechanisms of action, and current challenges related to anti-tumor small molecule inhibitors targeting various classes of RING-type E3 ligases. Further studies on the mechanisms of RING-type E3 ligases in the treatment of digestive system tumors will aid in identifying new targets and provide theoretical support and research strategies for developing anti-tumor drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.